60 Degrees Pharma (NASDAQ: SXTP) posts updated clinical investor deck

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. reported that on January 8, 2026 it made a new investor presentation available in connection with a webinar hosted by RedChip Companies, Inc. The presentation, furnished as Exhibit 99.1, provides updated information on the company’s clinical development timelines and regulatory strategy.

The materials are provided under Regulation FD and are stated as being furnished rather than filed, meaning they are not automatically incorporated into other securities law reports. The company notes that the presentation contains forward-looking statements and cautions that actual results may differ due to various risks and uncertainties.

false 0001946563 DC 0001946563 2026-01-08 2026-01-08 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2026-01-08 2026-01-08 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2026-01-08 2026-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 8, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SXTP		The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock		SXTPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 8, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) made available an investor presentation in connection with a webinar presentation hosted by RedChip Companies, Inc. The presentation includes, among other things, updated information regarding the Company’s clinical development timelines and regulatory strategy.

A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished pursuant to Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits

Exhibit Number		Description
99.1		Investor Presentation, dated January 8, 2026
104		Cover page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.
Date: January 8, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

2

FAQ

What did 60 Degrees Pharmaceuticals (SXTP) disclose in this report?

60 Degrees Pharmaceuticals made an investor presentation available on January 8, 2026, in connection with a webinar. The presentation, furnished as Exhibit 99.1, includes updated information on the company’s clinical development timelines and regulatory strategy.

How was the new 60 Degrees Pharmaceuticals (SXTP) investor presentation shared?

The company shared the investor presentation in connection with a webinar hosted by RedChip Companies, Inc. and furnished the slide deck as Exhibit 99.1 to this report.

What topics are covered in the 60 Degrees Pharmaceuticals (SXTP) investor presentation?

The investor presentation includes updated details on clinical development timelines and the company’s regulatory strategy, providing more current insight into its development plans.

Is the 60 Degrees Pharmaceuticals (SXTP) investor presentation considered filed with the SEC?

No. The company states that the information in this report, including Exhibit 99.1, is being furnished under Regulation FD and is not deemed to be “filed” for purposes of Section 18 of the Exchange Act or automatically incorporated into other securities law reports.

Does the 60 Degrees Pharmaceuticals (SXTP) presentation include forward-looking statements?

Yes. The company states that the presentation contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those described, and it does not undertake to update these statements except as required by law.

Where can investors find the 60 Degrees Pharmaceuticals (SXTP) investor presentation?

The presentation is included as Exhibit 99.1, titled “Investor Presentation, dated January 8, 2026,” to this report.